BOLD Stock Overview
A clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Boundless Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.35 |
| 52 Week High | US$12.65 |
| 52 Week Low | US$1.06 |
| Beta | 0 |
| 1 Month Change | -19.64% |
| 3 Month Change | -45.78% |
| 1 Year Change | -87.22% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.53% |
Recent News & Updates
Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn Situation
Jan 13
Will Boundless Bio (NASDAQ:BOLD) Spend Its Cash Wisely?
Sep 27Shareholder Returns
| BOLD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 22.7% | 4.9% | 6.8% |
| 1Y | -87.2% | -8.0% | 5.9% |
Return vs Industry: BOLD underperformed the US Biotechs industry which returned -8% over the past year.
Return vs Market: BOLD underperformed the US Market which returned 5.9% over the past year.
Price Volatility
| BOLD volatility | |
|---|---|
| BOLD Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: BOLD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BOLD's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 64 | Zach Hornby | boundlessbio.com |
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA. The company’s lead product candidate is ecDTx, BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. It develops BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1 demonstrating central nervous system penetrance in preclinical models.
Boundless Bio, Inc. Fundamentals Summary
| BOLD fundamental statistics | |
|---|---|
| Market cap | US$27.65m |
| Earnings (TTM) | -US$65.36m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs BOLD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOLD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$65.36m |
| Earnings | -US$65.36m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.93 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BOLD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/15 23:49 |
| End of Day Share Price | 2025/04/15 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Boundless Bio, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chris Shibutani | Goldman Sachs |
| Michael Schmidt | Guggenheim Securities, LLC |
| Andrew Berens | Leerink Partners LLC |